Ultralong-segment Barrett's Esophagus: Towards a Capsule-sponge Surveillance Strategy

Recruiting now · Not applicable

Conditions studied: Barrett Esophagus

In brief

The purpose of this study is to evaluate the Endosign capsule sponge test as a novel surveillance method in patients with an ultralong-segment Barrett's esophagus.

Key facts

Study ID

NCT06720636

Run by

Erasmus Medical Center

People needed

137

Starts

2025-02-03

Expected to finish

2027-09-01

Last updated by the study team

2025-08-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any participant 18 years and above, with ultralong-segment Barrett's esophagus and clinically fit for an endoscopy
• Ability to provide informed consent

You may not qualify if…

• Individuals with a diagnosis of an oro-pharynx, esophageal or gastro-esophageal tumor (T2 staging and above), or symptoms of dysphagia
• Esophageal varices or stricture requiring dilatation of the esophagus
• Individuals who have had a cerebrovascular event < 6 months prior where their swallowing has been affected
• Patients who have had previous treatments such as Photodynamic therapy (PDT), Radiofrequency ablation (RFA) or Argon Plasma Coagulation (APC) for dysplastic Barrett's esophagus
• Participants who are unable to provide informed consent
• Participants under age 18 years

Where it is running

• Erasmus Medisch Centrum — Rotterdam, South Holland, Netherlands (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.